Just a few years ago, it would have been unthinkable to offer testosterone therapy (TTh) to men with a history of prostate cancer. Yet several changes have occurred to make TTh a reasonable treatment option in men who are symptomatic from testosterone deficiency.
The relationship between T and prostate cancer has been a primary interest of mine, and it has been fascinating to watch the transformation in thought and practice over the last 20 years. In this article, I will present our current understanding of this topic and its impact on clinical practice.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.